ELVN

Enliven Therapeutics Stock Analysis

AI Rating

Neutral
  • Quality4/10
  • Growth↓ 2/10
  • Value↑ 5/10
Enliven Therapeutics sales and earnings growth
ELVN Growth
Fair
  • Revenue Y/Y↓ 0.00%
  • EPS Y/Y↓ 3.17%
  • FCF Y/Y↓ 4.08%
Enliven Therapeutics gross and profit margin trends
ELVN Profitability
Low
  • Gross margin ↓ 0.00%
  • EPS margin↓ 0.00%
  • ROIC 5Y↓ -90.36%
Enliven Therapeutics net debt vs free cash flow
ELVN Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↑ 999.0

Enliven Therapeutics stock volatility is in-line with the overall market. We give it a Great risk rating.

More Biotechnology stocks ↗